At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 198 enrolled
Drug / intervention
etoposide and cisplatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy Compared With Twice-daily Radiotherapy in Limited Small-cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide
In Brief
A Phase 2 clinical trial evaluating q.d. RT, b.i.d.RT, and 1 other intervention for Small Cell Lung Cancer. Targeting 198 participants across 1 site.
Detailed Summary
This Phase II randomized study is to determine whether once-daily simultaneous modulated accelerated thoracic radiotherapy (RT) resulted in better survival than twice-daily RT for patients with limited-stage small-cell lung cancer (LD-SCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2015
Primary CompletionSep 2020
Study CompletionDec 2021
TodayJul 2026
First PostedJan 14, 2015
Enrollment StartJan 1, 2015
Primary CompletionSep 30, 2020
Study CompletionDec 1, 2021
TodayJul 1, 2026
Enrollment to primary: 5.7 yearsPosted 11.5 years ago
Interventions
q.d. RTradiation
65 Gy in 26 fractions
b.i.d.RTradiation
45 Gy in 30 fractions
etoposide and cisplatindrug
etoposide and cisplatin concurrent with radiotherapy